At the Yacht Club de Monaco the Navicap Challenge - Trophée Elena Sivoldaeva 25-11-2024, 22:26

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Five charts that define the energy transition 12-12-2024, 22:19